Furthermore, abnormal DR6 expression has been suggested as a diagnostic or prognostic biomarker for some cancers, such as glioma, sarcoma, and ovarian cancer (Ren et al. 2022). Here, TNFRSF21 is linked to ovarian carcinoma.